Loading clinical trials...
Loading clinical trials...
An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Conditions
Interventions
RI-002
Locations
9
United States
IMMUNOe Health Centers
Cenntennial, Colorado, United States
Allergy Associates of the Palm Beaches, P.A.
North Palm Beach, Florida, United States
Family Allergy Center, PC
Atlanta, Georgia, United States
The South Bend Clinic, LLP
South Bend, Indiana, United States
Asthma & Immunology Associates
Omaha, Nebraska, United States
Mount Sinai School of Medicine
New York, New York, United States
Start Date
February 1, 2014
Primary Completion Date
December 1, 2014
Completion Date
January 1, 2015
Last Updated
October 5, 2016
NCT04232085
NCT03266653
NCT03266627
NCT04197596
NCT04354129
NCT02888535
Lead Sponsor
ADMA Biologics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions